Who was studied?
One patient with metastatic malignant perivascular epithelioid cell neoplasm after two surgeries.
What does the publication report?
Local symptoms were controlled and improvement in nonirradiated lesions was described.
Safety findings
The abstract lacks a detailed graded toxicity assessment.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report · DOI: 10.3389/fonc.2023.1045119 · PMID: 37143946
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.